Alyson Haslam

36PUBLICATIONS
36CO-AUTHORS
Cancer geneticsMolecular targetsCommunications and media policyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Sep 23, 2025
Age of Patients in Trials Submitted to the FDA Versus Age in Average Patients With Cancer.

Alyson Haslam, Vinay Prasad

|Aug 14, 2025
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials.

Varun Jhanji, Jacob Duncan, Taylor Gardner

|Jul 10, 2025
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials.

Varun Jhanji, Jacob Duncan, Taylor Gardner

|May 20, 2025
Characterization of bridging therapies in clinical trials leading to FDA approval of CAR-T cell therapies.

Victoria Kaestner, Alyson Haslam, Vinay Prasad

|Jan 31, 2025
How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis.

Alyson Haslam, Timothée Olivier, Vinay Prasad

Pageof 6